AlenCiken

Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3)

NASDAQ:OCGN   OCUGEN INC
Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

Third orphan drug designation for the same product

https://finance.yahoo.com/news/ocugen-gr...

TWITTER

It seems they received a Notice of Allowance for ANOTHER U.S. patent and just paid their fee last week. I assume we will hear about this too in addition to their latest orphan drug status designation? They have a lot of good news. A bit of insider purchases in May too.

I assume they will announce both soon. Typically no pr is made until the notice of issue is granted with the patent number & grant date. This happens shortly after the notice of allowance is granted and the fee is received (& other minor administrative items are completed).

It has not even started clinical trials yet! Face with tears of joy Lol!! orphan drug status means the costs to test and develop will be substantially subsidized by the government for public policy reasons. So this is basically an announcement that they received a free $150M.

According to the FDA website, $OCGN just received orphan drug status to complete its OCU400 modifier gene therapy platform! I have not seen any PR yet. They will also present at the World Orphan Drug Congress next month.

Comments

i am in heavy on OCGN. I have faith that they will see huge gains in the coming days, weeks, Months. I will be in and out a few times between now and then.
Reply
THANK YOU target price??
Reply
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out